FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SMITH IAN F (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					- <u>V</u> <u>M</u> 3. [Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 08/07/2017								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, CFO & COO					
50 NORTHERN AVENUE (Street) BOSTON MA 02210				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Si		(Zip)																
1. Title of Security (Instr. 3) 2. Trai			2. Transacti Date	ransaction		2A. Deemed Execution Date,		3.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amor Securiti Benefic		int of es ially Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)					
Common Stock				08/07/20	08/07/2017				M		4,250	A	\$77.3	31	120	120,138		D	
Common Stock				08/07/2017				S ⁽¹⁾		400	D	\$154.09) (2)(3)	119	9,738		D		
Common Stock				08/07/2017					S ⁽¹⁾		2,600	D	\$155.29	9(2)(4) 11		7,138		D	
Common Stock 08			08/07/20)17				S ⁽¹⁾		1,250	D	\$156.02	156.02 ⁽²⁾⁽⁵⁾		115,888		D		
Common Stock														5,306			Ι .	401(k)	
		7	able								sposed of , converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)	action	5. Number		6. Dat		cisable and	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owi Fori Dire or li (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amour or Number of Shares	er					
Stock Option (Right to Buy)	\$77.31	08/07/2017			M			4,250	(6)	02/04/2024	Commo Stock	ⁿ 4,250	0	\$0.00	8,500		D	

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Mr.\ Smith's\ company-approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$154.09 (range \$153.67 to \$154.50).
- 4. Open market sales reported on this line occurred at a weighted average price of \$155.29 (range \$154.82 to \$155.80).
- 5. Open market sales reported on this line occurred at a weighted average price of \$156.02 (range \$155.87 to \$156.26).
- 6. The option vests in 16 quarterly installments from 2/5/2014.

Remarks:

/s/ Omar White, Attorney-in-

08/09/2017

Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.